Published in J Clin Oncol on February 01, 2001
Evaluating and reporting dysphagia in trials of chemoirradiation for head-and-neck cancer. Int J Radiat Oncol Biol Phys (2009) 0.98
Paclitaxel Through the Ages of Anticancer Therapy: Exploring Its Role in Chemoresistance and Radiation Therapy. Cancers (Basel) (2015) 0.90
Long-term outcomes and toxicity of concurrent paclitaxel and radiotherapy for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys (2008) 0.90
Molecular and clinical responses in a pilot study of gefitinib with paclitaxel and radiation in locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys (2009) 0.89
Definitive radiochemotherapy of advanced head and neck cancer with carboplatin and paclitaxel : a phase II study. Strahlenther Onkol (2011) 0.82
The Role of the NF-kappaB Transcriptome and Proteome as Biomarkers in Human Head and Neck Squamous Cell Carcinomas. Biomark Med (2008) 0.80
[Preoperative radiochemotherapy of advanced resectable cancer of the oral cavity with cisplatin vs paclitaxel/carboplatin. Analysis of two multimodality treatment concepts]. Mund Kiefer Gesichtschir (2006) 0.80
Relation of mucous membrane alterations to oral intake during the first year after treatment for head and neck cancer. Head Neck (2010) 0.79
Concurrent use of vinorelbine and gefitinib induces supra-additive effect in head and neck squamous cell carcinoma cell lines. J Cancer Res Clin Oncol (2006) 0.77
Chemoradiation in Advanced Head and Neck Cancers: A Comparison of two Radiosensitizers, Paclitaxel and Cisplatin. Indian J Otolaryngol Head Neck Surg (2011) 0.76
Towards quantitative root hydraulic phenotyping: novel mathematical functions to calculate plant-scale hydraulic parameters from root system functional and structural traits. J Math Biol (2017) 0.76
Models for longitudinal data: a generalized estimating equation approach. Biometrics (1988) 27.90
Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res (1987) 10.80
Identification and expression cloning of a leptin receptor, OB-R. Cell (1995) 9.74
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol (1999) 9.22
The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat Genet (1993) 5.97
Two pleiotropic classes of daf-2 mutation affect larval arrest, adult behavior, reproduction and longevity in Caenorhabditis elegans. Genetics (1998) 5.37
Interacting genes in nematode dauer larva formation. Nature (1981) 5.21
Genes that regulate both development and longevity in Caenorhabditis elegans. Genetics (1995) 5.09
Control of C. elegans larval development by neuronal expression of a TGF-beta homolog. Science (1996) 4.23
Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med (1998) 3.79
Chemical biology of nitric oxide: Insights into regulatory, cytotoxic, and cytoprotective mechanisms of nitric oxide. Free Radic Biol Med (1998) 3.51
The daf-4 gene encodes a bone morphogenetic protein receptor controlling C. elegans dauer larva development. Nature (1993) 3.45
Sensory control of dauer larva formation in Caenorhabditis elegans. J Comp Neurol (1981) 3.41
daf-1, a C. elegans gene controlling dauer larva development, encodes a novel receptor protein kinase. Cell (1990) 3.16
Electroacupuncture for control of myeloablative chemotherapy-induced emesis: A randomized controlled trial. JAMA (2000) 3.13
Creating organized delivery systems: the barriers and facilitators. Hosp Health Serv Adm (1993) 2.88
Patient outcomes in alternative long-term care settings. Med Care (1978) 2.83
Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-beta 1. J Immunol (1991) 2.80
Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res (1999) 2.70
Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res (2001) 2.65
Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of radiosensitivity. Cancer Res (1987) 2.56
Conceptualizing and measuring integration: findings from the health systems integration study. Hosp Health Serv Adm (1993) 2.48
Serum hormones and the alcohol-breast cancer association in postmenopausal women. J Natl Cancer Inst (2001) 2.43
OATP1B1 polymorphism as a determinant of erythromycin disposition. Clin Pharmacol Ther (2012) 2.43
64-Slice computed tomography angiography in the diagnosis and assessment of coronary artery disease: systematic review and meta-analysis. Heart (2008) 2.42
Nitric oxide protects against cellular damage and cytotoxicity from reactive oxygen species. Proc Natl Acad Sci U S A (1993) 2.39
Physician-induced demand for surgery. J Health Econ (1986) 2.32
Induction of B2 RNA polymerase III transcription by heat shock: enrichment for heat shock induced sequences in rodent cells by hybridization subtraction. Nucleic Acids Res (1986) 2.31
Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci U S A (2000) 2.23
Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol (2000) 2.22
The multifaceted roles of nitric oxide in cancer. Carcinogenesis (1998) 2.19
The hidden mental health network. Treatment of mental illness by nonpsychiatrist physicians. Arch Gen Psychiatry (1985) 2.17
Nitric oxide potentiates hydrogen peroxide-induced killing of Escherichia coli. J Exp Med (1995) 2.14
Ischemic stroke injury is reduced in mice lacking a functional NADPH oxidase. Stroke (1997) 2.14
Sources of hospital cost variation by urban-rural location. Med Care (1987) 2.05
dpy-13: a nematode collagen gene that affects body shape. Cell (1988) 2.05
Viability measurements in mammalian cell systems. Anal Biochem (1989) 2.03
Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor. Clin Cancer Res (1999) 2.02
A role for leptin and its cognate receptor in hematopoiesis. Curr Biol (1996) 1.99
Inactivation of the HIV LTR by DNA CpG methylation: evidence for a role in latency. EMBO J (1990) 1.98
A decision model and cost-effectiveness analysis of colorectal cancer screening and surveillance guidelines for average-risk adults. Int J Technol Assess Health Care (2000) 1.94
Elevated thromboxane levels in the rat during endotoxic shock: protective effects of imidazole, 13-azaprostanoic acid, or essential fatty acid deficiency. J Clin Invest (1980) 1.91
Reaction kinetics for nitrosation of cysteine and glutathione in aerobic nitric oxide solutions at neutral pH. Insights into the fate and physiological effects of intermediates generated in the NO/O2 reaction. Chem Res Toxicol (1995) 1.90
Using concept mapping to develop a conceptual framework of staff's views of a supported employment program for individuals with severe mental illness. J Consult Clin Psychol (1994) 1.88
How accurate are Scottish cancer registration data? Br J Cancer (1994) 1.85
Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res (1996) 1.82
Constitutive activation of transcription factors NF-(kappa)B, AP-1, and NF-IL6 in human head and neck squamous cell carcinoma cell lines that express pro-inflammatory and pro-angiogenic cytokines. Mol Carcinog (1999) 1.81
Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival. Pigment Cell Melanoma Res (2007) 1.80
Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol (1998) 1.80
Molecular defect of the band 3 protein in southeast Asian ovalocytosis. N Engl J Med (1990) 1.77
Retinoid treatment of experimental allergic encephalomyelitis. IL-4 production correlates with improved disease course. J Immunol (1995) 1.76
On the spin trapping and ESR detection of oxygen-derived radicals generated inside cells. Proc Natl Acad Sci U S A (1986) 1.72
Squamous carcinoma presenting as an enlarged cervical lymph node. Cancer (1993) 1.71
Protein folds and functions. Structure (1998) 1.69
Fine structure of the Caenorhabditis elegans secretory-excretory system. J Ultrastruct Res (1983) 1.67
Binding of beta-amyloid to the p75 neurotrophin receptor induces apoptosis. A possible mechanism for Alzheimer's disease. J Clin Invest (1997) 1.66
Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force. Ann Neurol (1996) 1.64
Effects of vascular endothelial growth factor on hemodynamics and cardiac performance. J Cardiovasc Pharmacol (1996) 1.63
Hormone replacement therapy and colorectal adenoma recurrence among women in the Polyp Prevention Trial. J Natl Cancer Inst (2001) 1.62
The neurogenetics of mucolipidosis type IV. Neurology (2002) 1.62
Bromodeoxyuridine in tumors and chromosomes detected with a monoclonal antibody. J Clin Invest (1983) 1.59
Do nitroxide antioxidants act as scavengers of O2-. or as SOD mimics? J Biol Chem (1996) 1.59
Deletion in erythrocyte band 3 gene in malaria-resistant Southeast Asian ovalocytosis. Proc Natl Acad Sci U S A (1991) 1.59
Learning by doing in CABG surgery. Med Care (1990) 1.56
Developmental alterations in sensory neuroanatomy of the Caenorhabditis elegans dauer larva. J Comp Neurol (1983) 1.55
Protein recognition of adenylate: an example of a fuzzy recognition template. J Mol Biol (1996) 1.54
Physician behavior under the Medicare assignment option. J Health Econ (1982) 1.54
Oxoammonium cation intermediate in the nitroxide-catalyzed dismutation of superoxide. Proc Natl Acad Sci U S A (1992) 1.54
Prospective comparison of panoramic tomography (zonography) and helical computed tomography in the diagnosis and operative management of mandibular fractures. Plast Reconstr Surg (2001) 1.53
Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol (1992) 1.50
Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug. Clin Pharmacol Ther (2008) 1.50
The cytotoxicity of nitroxyl: possible implications for the pathophysiological role of NO. Arch Biochem Biophys (1998) 1.49
Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem Pharmacol (1998) 1.46
Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma. Mayo Clin Proc (1999) 1.46
IL (interleukin)-1alpha promotes nuclear factor-kappaB and AP-1-induced IL-8 expression, cell survival, and proliferation in head and neck squamous cell carcinomas. Clin Cancer Res (2001) 1.46
The usefulness of a predictive instrument to reduce inappropriate admissions to the coronary care unit. Ann Intern Med (1980) 1.45
In vitro studies of Taxol as a radiation sensitizer in human tumor cells. J Natl Cancer Inst (1994) 1.45
Comparison of one-, two-, and three-dimensional measurements of childhood brain tumors. J Natl Cancer Inst (2001) 1.43
Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J Clin Oncol (2001) 1.41
Effects of repeated days of intensified training on muscle glycogen and swimming performance. Med Sci Sports Exerc (1988) 1.41
Why do women physicians work fewer hours than men physicians? Inquiry (1984) 1.40
Heterogeneity in male to female risk for Parkinson's disease. J Neurol Neurosurg Psychiatry (2007) 1.40
An unusual case of postoperative hoarseness. Anaesthesia (1992) 1.39
A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer. Cancer Res (1994) 1.39
Use of terminology questioned. Br Dent J (1999) 1.39
A randomised phase II trial of epirubicin and 5-fluorouracil versus cisplatinum in the palliation of advanced and recurrent malignant tumour of the salivary glands. Br J Cancer (1993) 1.39
Predicting death and readmission after intensive care discharge. Br J Anaesth (2008) 1.39
Rhabdomyolysis and a "greenhouse effect". Lancet (1990) 1.38